We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





COVID-19 Study Finds High Rates of Unexplained Strokes and Delayed Recognition of Symptoms

By HospiMedica International staff writers
Posted on 23 Sep 2020
In a case series study that explored the association of COVID-19 and acute ischemic stroke, researchers have observed higher than expected rates of unexplained or “cryptogenic” strokes, as well as delays in stroke presentations or symptom recognition.

Ischemic stroke, caused by a clot that blocks blood flow to the brain, is the most common form of acute stroke. More...
But in some instances, despite looking for causes of these strokes - by a thorough cardiac evaluation (heart conditions are one of the most common causes); by looking at blood vessels supplying the brain or by testing for increased blood clotting conditions - the cause cannot be determined.

In the study, researchers from the Emory University Hospital (Atlanta, GA, USA) looked at COVID-19 patients with ischemic stroke. Out of 396 ischemic stroke patients admitted during the study period from March to July 2020, 13 were diagnosed with COVID-19. Researchers found the occurrence of stroke greater in COVID-19 patients who had risk factors like diabetes, hypertension, hyperlipidemia or atrial fibrillation/flutter. Males and African Americans were predominantly affected by strokes in the study.

“Interestingly, while cryptogenic strokes account for only 10-30% of all strokes, in our study we found it in 69% of the patient population which is extremely high and suggests the possibility of COVID-19 as a likely contributory factor in this presentation,” said Dinesh V. Jillella, assistant professor of neurology, Emory University School of Medicine. According to Jillella, as compared with the patients who did not have COVID-19, this was a statistically significant difference of 69% of strokes of cryptogenic etiology in the COVID-19 ischemic stroke group as compared to only 17% in the non-COVID ischemic stroke group.

Additionally, the study observed a prolonged average amount of time to presentation and symptom recognition averaging up to five days, a potential impact of the COVID crisis. These delays limited the use of acute reperfusion treatments, including drugs and surgery, to restore blood flow in or around the blocked vessels which can only be used when patients present within a 24-hour period. According to the researchers, the delayed presentations could be a result of patients waiting longer before coming to the hospital due to self-isolation or quarantine precautions or the fear of contracting COVID that have led to a general decline in acute stroke evaluations.

The study findings highlight the need for increased community awareness/education regarding the urgency of stroke symptoms and the need to ensure rapid evaluation to facilitate early stroke treatments. These findings support the idea that the hypercoagulable (increased clotting) state from COVID could contribute to stroke presentations and also show the issues with regards to delayed presentations and symptom identification in the setting of COVID.

Related Links:
Emory University Hospital


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Surgical System
Stealth AXiS
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Annotation platform for pixel-level labeling of free-text findings in 3D chest CT. (Baharoon M, Luo L, Moritz M, et al. ReXGroundingCT: A 3D chest CT dataset for segmentation of findings from free-text reports. NEJM AI. 2026;3(7). doi:10.1056/AIdbp2501220.)

Public Chest CT Dataset Supports Explainable AI in Diagnostic Radiology

Chest computed tomography scans generate complex three-dimensional images that can be difficult for artificial intelligence systems to explain clearly. Clinicians need to verify AI findings before using... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.